SCHEMBL1158096

SCHEMBL1158096

Cc1ccnc(Nc2cc3cc[nH]c(=O)c3c(NC[C@H](O)c3cccc(Cl)c3)n2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 20/20 0.46
CYP3A4 P08684 15/20 0.46
CYP2C19 P33261 10/20 0.46
CYP1A2 P05177 9/20 0.46
CYP2C9 P11712 9/20 0.46
EGFR P00533 2/20 0.40
INSR P06213 2/20 0.40
LCK P06239 2/20 0.40
KDR P35968 2/20 0.40
PTK2 Q05397 2/20 0.40
ERBB2 P04626 1/20 0.40
MET P08581 1/20 0.40
MAP2K1 Q02750 1/20 0.40
PLK4 O00444 1/20 0.40
CHEK1 O14757 1/20 0.40
AURKA O14965 1/20 0.40
PDPK1 O15530 1/20 0.40
DAPK3 O43293 1/20 0.40
DYRK3 O43781 1/20 0.40
JAK2 O60674 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1158759 1.00 IGF1R (0.46) IGF1RCYP3A4CYP2C19CYP1A2CYP2C9
SCHEMBL1158088 1.00 IGF1R (0.46) IGF1RCYP3A4CYP2C19CYP1A2CYP2C9
SCHEMBL12848859 0.93 FER (0.41) IGF1RCYP3A4CYP2C19CYP1A2CYP2C9
SCHEMBL12848843 0.93 FER (0.41) IGF1RCYP3A4CYP2C19CYP1A2CYP2C9
SCHEMBL1158623 0.84 SYK (0.39) IGF1RLCKKDRPTK2MAP2K1
SCHEMBL1158567 0.84 SYK (0.39) IGF1RLCKKDRPTK2MAP2K1
SCHEMBL1158677 0.82 SYK (0.40) IGF1RLCKKDRPTK2MAP2K1
SCHEMBL1158729 0.80 KARS1 (0.49) IGF1REGFRLCKKDRPTK2
SCHEMBL1158652 0.79 FER (0.41) IGF1RLCKKDRPTK2MAP2K1
SCHEMBL1158622 0.79 KARS1 (0.43) IGF1RLCKKDRPTK2MAP2K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US claimed
EP-2459556-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-06-06 EP disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS SYK, BTK, LYN IGF1R 1151/4885CYP3A4 4647/4885CYP2C19 4753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.